MCID: DFF029
MIFTS: 29

Diffuse Large B-Cell Lymphoma of the Central Nervous System

Categories: Blood diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Diffuse Large B-Cell Lymphoma of the Central Nervous System

MalaCards integrated aliases for Diffuse Large B-Cell Lymphoma of the Central Nervous System:

Name: Diffuse Large B-Cell Lymphoma of the Central Nervous System 58
Dlbcl of the Cns 58

Characteristics:

Orphanet epidemiological data:

58
diffuse large b-cell lymphoma of the central nervous system
Inheritance: Multigenic/multifactorial,Not applicable;

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

ICD10 via Orphanet 33 C83.3
Orphanet 58 ORPHA300849

Summaries for Diffuse Large B-Cell Lymphoma of the Central Nervous System

MalaCards based summary : Diffuse Large B-Cell Lymphoma of the Central Nervous System, also known as dlbcl of the cns, is related to diffuse large b-cell lymphoma and b-cell lymphoma. An important gene associated with Diffuse Large B-Cell Lymphoma of the Central Nervous System is MYC (MYC Proto-Oncogene, BHLH Transcription Factor), and among its related pathways/superpathways are Measles and Gastric cancer. The drugs Sargramostim and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include testis, t cells and pineal.

Related Diseases for Diffuse Large B-Cell Lymphoma of the Central Nervous System

Diseases related to Diffuse Large B-Cell Lymphoma of the Central Nervous System via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 36)
# Related Disease Score Top Affiliating Genes
1 diffuse large b-cell lymphoma 31.3 MYC BCL2
2 b-cell lymphoma 31.3 MYC BCL2
3 follicular lymphoma 30.2 MYC BCL2
4 primary central nervous system lymphoma 11.6
5 lymphoma 11.0
6 central nervous system lymphoma 10.6
7 47,xyy 10.5
8 systemic lupus erythematosus 10.3
9 aspergillosis 10.3
10 peripheral t-cell lymphoma 10.3
11 lymphoproliferative syndrome 10.3
12 dementia 10.3
13 uveitis 10.3
14 lupus erythematosus 10.3
15 post-transplant lymphoproliferative disease 10.3
16 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 9.8 MYC BCL2
17 intravascular large b-cell lymphoma 9.8 MYC BCL2
18 suppressor of tumorigenicity 3 9.8 MYC BCL2
19 alk-negative anaplastic large cell lymphoma 9.8 MYC BCL2
20 reticulosarcoma 9.8 MYC BCL2
21 inflammatory myofibroblastic tumor 9.8 MYC BCL2
22 lymphoma, mucosa-associated lymphoid type 9.8 MYC BCL2
23 li-fraumeni syndrome 9.8 MYC BCL2
24 nervous system cancer 9.8 MYC BCL2
25 mantle cell lymphoma 9.8 MYC BCL2
26 t-cell lymphoblastic leukemia/lymphoma 9.8 MYC BCL2
27 breast adenocarcinoma 9.8 MYC BCL2
28 adenocarcinoma 9.8 MYC BCL2
29 burkitt lymphoma 9.7 MYC BCL2
30 leukemia, chronic myeloid 9.7 MYC BCL2
31 wilms tumor 1 9.7 MYC BCL2
32 nasopharyngeal carcinoma 9.7 MYC BCL2
33 lung cancer susceptibility 3 9.7 MYC BCL2
34 squamous cell carcinoma, head and neck 9.6 MYC BCL2
35 lymphoma, non-hodgkin, familial 9.6 MYC BCL2
36 cervical cancer 9.5 MYC BCL2

Graphical network of the top 20 diseases related to Diffuse Large B-Cell Lymphoma of the Central Nervous System:



Diseases related to Diffuse Large B-Cell Lymphoma of the Central Nervous System

Symptoms & Phenotypes for Diffuse Large B-Cell Lymphoma of the Central Nervous System

Drugs & Therapeutics for Diffuse Large B-Cell Lymphoma of the Central Nervous System

Drugs for Diffuse Large B-Cell Lymphoma of the Central Nervous System (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 33)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sargramostim Approved, Investigational Early Phase 1 123774-72-1, 83869-56-1
2
Etoposide Approved Early Phase 1 33419-42-0 36462
3
Levoleucovorin Approved, Investigational Early Phase 1 68538-85-2 149436
4
Methotrexate Approved Early Phase 1 1959-05-2, 59-05-2 126941
5
Vincristine Approved, Investigational Early Phase 1 2068-78-2, 57-22-7 5978
6
Prednisone Approved, Vet_approved Early Phase 1 53-03-2 5865
7
rituximab Approved Early Phase 1 174722-31-7 10201696
8
Doxorubicin Approved, Investigational Early Phase 1 23214-92-8 31703
9
Cyclophosphamide Approved, Investigational Early Phase 1 50-18-0, 6055-19-2 2907
10
Folic acid Approved, Nutraceutical, Vet_approved Early Phase 1 59-30-3 6037
11
Molgramostim Investigational Early Phase 1 99283-10-0
12 Folic Acid Antagonists Early Phase 1
13 Tubulin Modulators Early Phase 1
14 Vitamin B9 Early Phase 1
15 Antibiotics, Antitubercular Early Phase 1
16 Etoposide phosphate Early Phase 1
17 Immunosuppressive Agents Early Phase 1
18
Liposomal doxorubicin Early Phase 1 31703
19 Antineoplastic Agents, Immunological Early Phase 1
20 Antimitotic Agents Early Phase 1
21 Hormone Antagonists Early Phase 1
22 Antirheumatic Agents Early Phase 1
23 Immunologic Factors Early Phase 1
24 Antineoplastic Agents, Hormonal Early Phase 1
25 glucocorticoids Early Phase 1
26 Alkylating Agents Early Phase 1
27 Vitamin B Complex Early Phase 1
28 Hormones Early Phase 1
29 Dermatologic Agents Early Phase 1
30 Folate Early Phase 1
31 Antimetabolites Early Phase 1
32 Anti-Bacterial Agents Early Phase 1
33 Anti-Inflammatory Agents Early Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Use of Dose Adjusted EPOCH-R in the Treatment of Childhood Mature B Cell Malignancies Completed NCT01760226 Early Phase 1 DA-EPOCH-R for DLBCL, PTLD, AND PMBCL;Methotrexate;Etoposide;Doxorubicin;Vincristine;Rituximab;Cyclophosphamide;Prednisone;G-CSF

Search NIH Clinical Center for Diffuse Large B-Cell Lymphoma of the Central Nervous System

Genetic Tests for Diffuse Large B-Cell Lymphoma of the Central Nervous System

Anatomical Context for Diffuse Large B-Cell Lymphoma of the Central Nervous System

MalaCards organs/tissues related to Diffuse Large B-Cell Lymphoma of the Central Nervous System:

40
Testis, T Cells, Pineal

Publications for Diffuse Large B-Cell Lymphoma of the Central Nervous System

Articles related to Diffuse Large B-Cell Lymphoma of the Central Nervous System:

(show all 45)
# Title Authors PMID Year
1
GCB-type is a favorable prognostic factor in primary CNS diffuse large B-cell lymphomas. 61
33339691 2021
2
Primary large B-cell lymphoma of the central nervous system with cyclin D1 expression and t(11;14) (IGH-CCND1): Diffuse large B-cell lymphoma with CCND1 rearrangement or mantle cell lymphoma? 61
32639587 2020
3
Expression of programmed cell death ligand-1 by immune cells in the microenvironment is a favorable prognostic factor for primary diffuse large B-cell lymphoma of the central nervous system. 61
33269495 2020
4
Diffuse Large B-Cell Lymphoma of the Central Nervous System Manifesting with Intratumoral Hemorrhage: A Case Report and Literature Review. 61
32763371 2020
5
Clonal Evolution in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System. 61
29629945 2020
6
Immune Checkpoint Molecules in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System. 61
33613887 2020
7
Primary Central Nervous System Lymphoma in a Patient on Adalimumab Therapy for Chronic Plaque Psoriasis. 61
32247793 2020
8
Redox reaction and clinical outcome of primary diffuse large B-cell lymphoma of the central nervous system: Prognostic role of metabolic and textural parameters of 62Cu-diacetyl-bis (N4-methylthiosemicarbazone) PET/computed tomography in a small patient cohort. 61
32371672 2020
9
Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system - an international study of feasibility and efficacy in routine clinical practice. 61
31997308 2020
10
Diffuse large B-cell lymphoma variants: an update. 61
31735345 2020
11
Tumor and Cerebrospinal Fluid microRNAs in Primary Central Nervous System Lymphomas. 61
31731456 2019
12
Clinicopathological analysis of sinonasal malignant lymphoma in an HTLV-1 endemic area in Japan -special focus on primary sinonasal diffuse large B-cell lymphoma. 61
31391402 2019
13
Branched clonal evolution: nodal follicular lymphoma and primary diffuse large B-cell lymphoma of the central nervous system. 61
30890596 2019
14
Delayed Contrast Enhancement in Magnetic Resonance Imaging and Vascular Morphology of Primary Diffuse Large B-Cell Lymphoma (DLBCL) of the Central Nervous System (CNS): A Retrospective Study. 61
31055591 2019
15
Secondary diffuse large B cell lymphoma of the central nervous system: retrospective review of case series. 61
30182348 2019
16
Diffuse large B-cell lymphoma of the central nervous system presenting as "lymphomatosis cerebri" and dementia in elderly man: Case report and review of the literature. 61
30732171 2019
17
Aggressive B cell lymphomas in the 2017 revised WHO classification of tumors of hematopoietic and lymphoid tissues. 61
30380402 2019
18
High tumoral PD-L1 expression and low PD-1+ or CD8+ tumor-infiltrating lymphocytes are predictive of a poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system. 61
31428525 2019
19
A Rare Case of Spontaneous Remission and Relapse of a Primary Central Nervous System Lymphoma. 61
30684376 2018
20
Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy. 61
30370365 2018
21
An Autopsy Case of Epstein-Barr Virus-Associated Diffuse Large B-Cell Lymphoma of the Central Nervous System in an Immunocompromised Host. 61
28774170 2018
22
Prognostic implications of tumor-infiltrating macrophages, M2 macrophages, regulatory T-cells, and indoleamine 2,3-dioxygenase-positive cells in primary diffuse large B-cell lymphoma of the central nervous system. 61
29900049 2018
23
[Clinical Analysis of Combination Chemotherapy Using High Dose Methotrexate, Rituximab, and Vincristine with or without Procarbazine for Elderly Patients with Diffuse Large B-Cell Lymphoma of the Central Nervous System]. 61
29361628 2017
24
Development of Epstein-Barr Virus-related Primary Diffuse Large B-cell Lymphoma of the Central Nervous System in a Patient with Peripheral T-cell Lymphoma, Not Otherwise Specified after Mogamulizumab Treatment. 61
28924126 2017
25
B-cell posttransplant lymphoproliferative disorder isolated to the central nervous system is Epstein-Barr virus positive and lacks p53 and Myc expression by immunohistochemistry. 61
27993575 2017
26
EBV-positive post-transplant lymphoproliferative disorder presenting as primary diffuse large B-cell lymphoma of the central nervous system. 61
28984115 2017
27
Clinicopathological features of primary diffuse large B-cell lymphoma of the central nervous system - strong EZH2 expression implying diagnostic and therapeutic implication. 61
27807891 2016
28
Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors. 61
27825110 2016
29
MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system. 61
27286976 2016
30
Primary diffuse large B-cell lymphoma of the central nervous system: A case report and literature review. 61
27123068 2016
31
STAT3 activation is associated with cerebrospinal fluid interleukin-10 (IL-10) in primary central nervous system diffuse large B cell lymphoma. 61
26080800 2015
32
MYC protein expression is associated with poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system. 61
26010683 2015
33
Primary diffuse large B-cell lymphoma of the central nervous system in pineal gland: Report of a rare case with review of literature. 61
26275286 2015
34
Secondary diffuse large B-cell lymphoma of the central nervous system: the need for better predictors. 61
26099732 2015
35
Primary central nervous system lymphoma mimicking recurrent depressive disorder: A case report. 61
25789049 2015
36
Differential expression of Toll-like receptor (TLR) and B cell receptor (BCR) signaling molecules in primary diffuse large B-cell lymphoma of the central nervous system. 61
25391967 2015
37
Diagnostic value of interleukin-10 in cerebrospinal fluid for diffuse large B-cell lymphoma of the central nervous system. 61
25258254 2015
38
MYC protein expression in primary diffuse large B-cell lymphoma of the central nervous system. 61
25479599 2014
39
Current strategies in the diagnosis of diffuse large B-cell lymphoma of the central nervous system. 61
22077417 2012
40
[Analysis of the immunohistochemical subtypes and prognosis of primary diffuse large B cell lymphoma of the central nervous system]. 61
22780928 2012
41
Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. 61
21200023 2011
42
Diffuse large B-cell lymphoma involving the central nervous system. 61
21087986 2011
43
Diffuse large B-cell lymphoma of the central nervous system in mycophenolate mofetil-treated patients with systemic lupus erythematosus. 61
19897521 2010
44
From brain to testis: immune escape and clonal selection in a B cell lymphoma with selective outgrowth in two immune sanctuaries [correction of sanctuariesy]. 61
17650453 2007
45
Epstein Barr virus-associated lymphoma in HIV-infected children. 61
12092768 2002

Variations for Diffuse Large B-Cell Lymphoma of the Central Nervous System

Expression for Diffuse Large B-Cell Lymphoma of the Central Nervous System

Search GEO for disease gene expression data for Diffuse Large B-Cell Lymphoma of the Central Nervous System.

Pathways for Diffuse Large B-Cell Lymphoma of the Central Nervous System

Pathways related to Diffuse Large B-Cell Lymphoma of the Central Nervous System according to GeneCards Suite gene sharing:

(show all 30)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.36 MYC BCL2
2
Show member pathways
12.31 MYC BCL2
3
Show member pathways
12.28 MYC BCL2
4
Show member pathways
12.25 MYC BCL2
5
Show member pathways
12.24 MYC BCL2
6
Show member pathways
12.18 MYC BCL2
7
Show member pathways
12.15 MYC BCL2
8
Show member pathways
12.14 MYC BCL2
9
Show member pathways
12.12 MYC BCL2
10 12.08 MYC BCL2
11
Show member pathways
12.04 MYC BCL2
12
Show member pathways
11.97 MYC BCL2
13
Show member pathways
11.94 MYC BCL2
14 11.82 MYC BCL2
15
Show member pathways
11.78 MYC BCL2
16 11.74 MYC BCL2
17
Show member pathways
11.66 MYC BCL2
18 11.58 MYC BCL2
19 11.57 MYC BCL2
20
Show member pathways
11.48 MYC BCL2
21 11.44 MYC BCL2
22 11.35 MYC BCL2
23
Show member pathways
11.26 MYC BCL2
24 11.19 MYC BCL2
25 11.03 MYC BCL2
26 10.97 MYC BCL2
27
Show member pathways
10.9 MYC BCL2
28 10.6 MYC BCL2
29
Show member pathways
10.3 MYC BCL2

GO Terms for Diffuse Large B-Cell Lymphoma of the Central Nervous System

Biological processes related to Diffuse Large B-Cell Lymphoma of the Central Nervous System according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular response to DNA damage stimulus GO:0006974 9.4 MYC BCL2
2 regulation of gene expression GO:0010468 9.37 MYC BCL2
3 response to drug GO:0042493 9.32 MYC BCL2
4 cytokine-mediated signaling pathway GO:0019221 9.26 MYC BCL2
5 cellular response to hypoxia GO:0071456 9.16 MYC BCL2
6 branching involved in ureteric bud morphogenesis GO:0001658 8.96 MYC BCL2
7 response to gamma radiation GO:0010332 8.62 MYC BCL2

Molecular functions related to Diffuse Large B-Cell Lymphoma of the Central Nervous System according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription factor binding GO:0008134 8.96 MYC BCL2
2 repressing transcription factor binding GO:0070491 8.62 MYC BCL2

Sources for Diffuse Large B-Cell Lymphoma of the Central Nervous System

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....